Pregled bibliografske jedinice broj: 664813
Addition of rituximab to high-dose methotrexate-based chemotherapy improves survival of adults with Burkitt lymphoma / leukemia
Addition of rituximab to high-dose methotrexate-based chemotherapy improves survival of adults with Burkitt lymphoma / leukemia // Acta haematologica, 127 (2012), 2; 115-117 doi:10.1159/000334705 (međunarodna recenzija, pismo, znanstveni)
CROSBI ID: 664813 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Addition of rituximab to high-dose methotrexate-based chemotherapy improves survival of adults with Burkitt lymphoma / leukemia
Autori
Dujmović, Dino ; Aurer, Igor ; Radman, Ivo ; Serventi-Seiwerth, Ranka ; Dotlić, Snježana ; Štern-Padovan, Ranka ; Dubravčić, Klara ; Šantek, Fedor ; Labar, Boris
Izvornik
Acta haematologica (0001-5792) 127
(2012), 2;
115-117
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, pismo, znanstveni
Ključne riječi
Burkitt lymphoma; rituximab; methotrexate; combined antineoplastic chemotherapy protocols
Sažetak
The paper describes our results in treatment of Burkitt lymphoma / leukemia with rituximab and high-dose methotrexate based chemotherapy.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Projekti:
108-1081872-1908 - Dijagnostika i liječenje limfoma (Aurer, Igor, MZOS ) ( CroRIS)
Ustanove:
Medicinski fakultet, Zagreb,
Klinički bolnički centar Zagreb
Profili:
Ranka Štern-Padovan
(autor)
Dino Dujmović
(autor)
KLARA DUBRAVČIĆ
(autor)
Boris Labar
(autor)
Ranka Serventi-Seiwerth
(autor)
Fedor Šantek
(autor)
Igor Aurer
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- SCI-EXP, SSCI i/ili A&HCI